Nephros (NEPH) Q1 2025 earnings summary

Executive summary

• Net revenue rose 38% year-over-year to $4.9 million for Q1 2025, driven by strong programmatic and emergency response sales.

• Achieved net income of $558,000, reversing a net loss of $169,000 in Q1 2024, marking only the second quarterly net income in company history.

• Gross margin improved to 65% from 62% year-over-year, reflecting favorable product mix and price increases.

• Adjusted EBITDA improved to $667,000 from ($95,000) in the prior year period.

• Company operates a single segment focused on high-performance water filtration for medical and commercial markets.

Financial highlights

• Product revenues increased to $4.7 million from $3.5 million year-over-year; royalty and other revenues rose to $0.2 million from $0.02 million.

• Operating income was $0.6 million, up from a loss of $0.2 million in Q1 2024.

• EPS was $0.05 (basic and diluted), compared to $(0.02) in the prior year.

• Cash and cash equivalents totaled $4.1 million at March 31, 2025, up from $3.8 million at year-end 2024, with no debt outstanding.

• Working capital improved to $7.5 million from $6.7 million at year-end.

Outlook and guidance

• Management anticipates continued focus on sales growth, innovation, and expense control to maintain profitability and positive cash flow.

• Emergency response business is expected to normalize and not persist at Q1 levels due to regulatory and administrative changes.

• Company believes cash balances are sufficient for at least the next 12 months; may reduce discretionary spending if results fall short.